Cumberland Pharmaceuticals (CPIX) Commences Portaban Phase 2 in Portal Hypertension
- Wall Street falls with financials, other post-election gainers
- The FTC Confirms Antitrust Charges Against Qualcomm (QCOM) for Monopolizing Semiconductor Device Used in Cell Phones
- United Airlines (UAL) Tops Q4 EPS by 5c
- Obama shortens sentence of Manning, who gave secrets to WikiLeaks
- After-Hours Stock Movers 01/17: (SHLO) Higher; (GIMO) (AFAM) (CSX) Lower (more...)
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced the initiation of a new Phase II clinical program of Portaban™ for patients with portal hypertension associated with liver disease. The U.S. Food and Drug Administration (FDA) has cleared Cumberland's investigational new drug application (IND) for a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study.
Portaban™ is an oral formulation of ifetroban and the fourth development candidate in Cumberland's pipeline. Preclinical studies have shown ifetroban can reduce portal pressure, necrosis, inflammation, and fibrosis in multiple models of liver injury.
"We are very encouraged by the preclinical findings supporting the use of Portaban™ and its potential as a new therapy for liver cyrossis patients," said A.J. Kazimi, Cumberland's Chief Executive Officer. "We remain focused on developing products that address unmet medical needs."
"I am excited to investigate a drug candidate with the potential to induce a clinically meaningful reduction in severe portal hypertension over a relatively short time frame." said Dr. Don Rockey, lead investigator at the Medical Center of South Carolina. "Portal hypertension is largely responsible for events of hepatic decompensation including variceal bleeding, ascites, and encephalopathy, which contribute substantially to morbidity and mortality in these patients. By lowering elevated portal pressures, Portaban™ has the potential to decrease the risk of hepatic decompensation in liver cirrhosis patients over the short term, and may improve both liver function and structure over the long term through anti-inflammatory and anti-fibrotic effects."
Cumberland previously completed an initial Phase II study for Boxaban® (ifetroban) for patients with aspirin-exacerbated respiratory disease (AERD), a disease involving chronic asthma that is worsened by aspirin. The Company has also completed an initial Phase II study for Hepatoren® (ifetroban) in patients with Hepatorenal Syndrome (HRS), a life-threatening condition involving progressive kidney failure.
Earlier this year, Cumberland announced the start of another Phase II clinical program with Vasculan™ (ifetroban) for the treatment of systemic sclerosis, a rare and life-threatening autoimmune disorder that affects the skin and internal organs.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Caesars Entertainment (CZR) Announces Confirmation of CEOC's Plan of Reorganization
- Deutsche Bank CEO apologizes for conduct in toxic mortgages case
- Endologix (ELGX) Resumes Shipping AFX2 Endovascular AAA Systems
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments
Related EntitiesDefinitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!